Phase 1 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• A confirmed diagnosis of non-small cell lung cancer (NSCLC), verified by a tissue or cell sample from a pathology lab.
• The cancer must be measurable on scans and not able to be removed with surgery.
• Test results showing a PD-L1 score of 1% or higher at any point since diagnosis, using an FDA-approved testing device.
• The cancer has gotten worse after receiving a standard first-line treatment approved by the FDA for NSCLC.
• People aged 18 or older.
• A general health/activity level score of 2 or less on the ECOG scale, meaning the person is able to care for themselves and is up and about more than half of waking hours (confirm with trial site).
• Blood and organ function within acceptable ranges, including healthy enough levels of white blood cells, platelets, liver function, and kidney function.
• People who have had brain metastases that were already treated may be eligible, as long as follow-up brain scans show the cancer has not grown back there.
• People with new or growing brain metastases may be eligible if immediate brain-specific treatment is not urgently needed right away or during the first treatment cycle.
• People living with HIV who are on effective HIV medication and have had an undetectable viral load in the 6 months before starting the study.
• People with a chronic hepatitis B infection whose virus levels are undetectable while on appropriate treatment.
• People with a history of hepatitis C who have been successfully treated and cured, or who are currently being treated and have an undetectable hepatitis C viral load.
• People who are able to become pregnant must agree to use effective contraception from the start of the study until 4 months after finishing treatment (abstinence is also accepted if that is the person's usual lifestyle).
• People who are currently breastfeeding must be willing to stop breastfeeding for the full duration of the study treatment.
• Willingness and ability to understand and sign a written consent form to participate in the study.

Who may not be able to join:

• People who are currently taking part in another clinical trial involving an experimental treatment.
• People with an ongoing active Epstein-Barr virus or cytomegalovirus infection.
• People with a history of serious allergic reactions to medicines that are chemically or biologically similar to pembrolizumab, aztreonam, vancomycin, or albuterol.
• People who are pregnant at the time of screening.
• People whose lung function is significantly reduced — specifically, where a breathing test result called FEV1 is below 25% — due to the requirement to receive one of the study drugs as an inhaled mist.
• People with a history of severe immune-related side effects from previous treatment, including any nerve or heart-related immune reactions at any severity level, any grade 3 or 4 immune reaction (except hormone-related ones that are fully managed with supplementation), or any immune-related lung inflammation.
• People with ongoing, uncontrolled health conditions that would make it difficult to follow the study requirements.

Important: Always verify eligibility with the trial site directly before applying.